Automated urinalysis systems are valuable tools in clinical laboratories, especially those with a high work load. The objective of this study was to compare the analytical performance of Sysmex UN series urine analyser, which may become a new one in our laboratory, with the Cobas 6500 automated urine analyser, which is used in our laboratory for a long time. For comparisons, manual microscopical examination was accepted as reference method. A total of 470 urine samples were tested in the two automated urinalysis systems, and urine sediment testing with manual microscopy was applied to a 100 pathological samples of the total 470. The diagnostic performance of the two automated urine analysers was compared with each other and manual microscopy. Differences were determined between automated and manual microscopy in some pathological samples. The resultant regression equations were as follows. Comparison of Cobas U701 with Sysmex UF-5000: y = - 0.57 (- 0.85 to - 0.29) + 0.95 (0.92 to 0.99) x for RBC, and y = - 0.11 (- 0.54 to 0.29) + 0.89 (0.84 to 0.98) x for WBC; comparison of Cobas U701 with manual microscopy: y = - 0.45 (- 0.85 to 0.21) + 1.00 (0.92 to 1.07) x for WBC; and comparison of Sysmex UF-5000 with manual microscopy: y = - 0.74 (- 1.09 to - 0.57) + 0.87 (0.85 to 0.91) x for WBC. We can conclude that the new Sysmex UN series urine analyser can be safely used in our laboratory. Although the results showed good to moderate concordance, the microscopy results of the automated platforms should be confirmed by manual microscopy, particularly in pathological samples.
Background/Objectives: The global prevalence of obesity and type 2 diabetes mellitus (T2DM) has been steadily increasing, and these interrelated disorders share common pathophysiological mechanisms, including altered levels of adipokines secreted from adipose tissue. Among these, chemerin and visfatin have been suggested as potential biomarkers for obesity-related metabolic dysfunction. This study aimed to evaluate the relationship between serum chemerin and visfatin levels and obesity in patients with T2DM. Methods: The study included 74 obese T2DM patients, 60 non-obese T2DM patients, and 36 healthy controls. Serum chemerin and visfatin levels were measured using an enzyme-linked immunosorbent assay (ELISA). Clinical parameters including HbA1c, fasting plasma glucose, insulin, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were assessed. Between-group comparisons were performed using appropriate parametric or non-parametric tests with Bonferroni correction for multiple comparisons. ROC curve analysis was applied to evaluate the diagnostic performance of visfatin. Results: Serum visfatin levels were significantly higher in the T2DM (33.00 ± 20.61) groups compared to controls (30.25 ± 26.40; p = 0.01), while chemerin levels showed no significant difference. HbA1c and glucose levels were elevated in both diabetic groups, whereas insulin and HOMA-IR were significantly higher only in the obese T2DM group. Receiver operating characteristic (ROC) analysis revealed limited diagnostic accuracy of visfatin (AUC < 0.70). Conclusions: Visfatin levels were modestly higher in obese T2DM patients, while chemerin did not differ significantly among groups. However, the diagnostic performance of visfatin was limited (AUC < 0.70), and these findings should be regarded as exploratory. Larger, well-controlled studies are required to clarify whether visfatin or chemerin could have any clinical utility as part of multi-marker approaches.
In this study, xanthine oxidase (XO), malondialdehyde (MDA), myeloperoxidase (MPO) and glutathione (GSH) levels in the ovarian tissues of rats during the development of ischemia and postischemia-induced reperfusion were investigated, and the effect of ATP on ischemia-reperfusion (I/R) damage was biochemically and histopathologically examined. The results of the biochemical analyses demonstrated that ATP significantly reduced the level of XO and MDA and increased the amount of GSH in both ischemia and I/R-applied ovarian tissue at the doses administered. Furthermore, ATP significantly suppressed the increase in MPO activity that occurred following the application of post ischemia reperfusion in the ovarian tissue. The biochemical results obtained in the present study coincide with the histological findings. The severity of the pathological findings, such as dilatation, congestion, haemorrhage, oedema and polymorphonuclear nuclear leukocytes (PMNLs), increased in parallel with the increase observed in the products of XO metabolism. In conclusion, exogenously applied ATP prevented I/R damage by reducing the formation of XO in ischemic ovarian tissue.
1 October 2013 in European Journal of Obstetrics & Gynecology and Reproductive Biology